• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Deseja Trust claimed ownership of 17,960,146 units of Ordinary Shares

    10/8/21 5:19:25 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PROC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Deseja Trust

    (Last) (First) (Middle)
    29 BANCROFT MILLS ROAD

    (Street)
    WILMINGTON DE 19806

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/29/2021
    3. Issuer Name and Ticker or Trading Symbol
    Procaps Group, S.A. [ PROC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares 17,960,146(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Includes 2,794,372 Ordinary Shares held in escrow subject to release pursuant to the terms of that certain Transaction Support Agreement, dated as of March 31, 2021 by and between Crynssen Pharma Group Limited, Procaps Group, S.A., Union Acquisition Corp. II and those other persons and entities signatories thereto.
    Remarks:
    See Exhibit 24.1 - Power of Attorney by the Deseja Trust
    /s/ Flora Perez, Attorney-in-Fact for the Deseja Trust 10/08/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PROC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PROC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PROC
    SEC Filings

    See more
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      2/19/25 8:56:19 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      2/3/25 9:00:03 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      1/16/25 8:30:04 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Procaps Group Receives Delisting Notice From Nasdaq

      MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

      2/3/25 8:50:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Receives Additional Delinquency Letter

      MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

      1/3/25 4:15:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

      MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

      12/20/24 4:53:03 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Leadership Updates

    Live Leadership Updates

    See more
    • Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

      MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

      12/20/24 4:53:03 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Statement from the Board of Directors of Procaps Group

      Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

      12/21/23 6:45:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

      Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

      11/22/23 8:30:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      12/3/24 7:20:10 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      10/29/24 9:46:26 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      10/28/24 8:42:14 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Manieu Alexandre Weinstein claimed ownership of 15,877,516 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/12/21 9:32:55 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Minski Ruben claimed ownership of 31,338,454 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/8/21 5:22:21 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Minski Jose claimed ownership of 17,960,146 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/8/21 5:20:55 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Financials

    Live finance-specific insights

    See more
    • Procaps Group Reports Third Quarter 2023 Results

      Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

      12/26/23 5:40:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Update on Third Quarter Results

      Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

      11/14/23 5:25:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

      Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

      11/10/23 11:37:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care